Evidence map›Paper›PMID 30894471›Full record

ArticleJournal of virology2019

Mutations That Increase the Stability of the Postfusion gp41 Conformation of the HIV-1 Envelope Glycoprotein Are Selected by both an X4 and R5 HIV-1 Virus To Escape Fusion Inhibitors Corresponding to Heptad Repeat 1 of gp41, but the gp120 Adaptive Mutations Differ between the Two Viruses.

Min Zhuang, Russell Vassell, Chen Yuan, Paul W Keller, Hong Ling, Wei Wang, Carol D Weiss

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Min ZhuangDepartment of Microbiology, Harbin Medical University, Harbin, China zhuangm@ems.hrbmu.edu.cn carol.weiss@fda.hhs.gov.
Russell VassellCenter for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
Chen YuanDepartment of Microbiology, Harbin Medical University, Harbin, China.
Paul W KellerCenter for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
Hong LingDepartment of Microbiology, Harbin Medical University, Harbin, China.
Wei WangCenter for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
Carol D WeissCenter for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA zhuangm@ems.hrbmu.edu.cn carol.weiss@fda.hhs.gov.ORCID 0000-0002-9965-1289
Center for Biologics Evaluation and Research · USHarbin Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Binding of the gp120 surface subunit of the envelope glycoprotein (Env) of HIV-1 to CD4 and chemokine receptors on target cells triggers refolding of the gp41 transmembrane subunit into a six-helix bundle (6HB) that promotes fusion between virus and host cell membranes. To elucidate details of Env entry and potential differences between viruses that use CXCR4 (X4) or CCR5 (R5) coreceptors, we generated viruses that are resistant to peptide fusion inhibitors corresponding to the first heptad repeat region (HR1) of gp41 that target fusion-intermediate conformations of Env. Previously we reported that an R5 virus selected two resistance pathways, each defined by an early gp41 resistance mutation in either HR1 or the second heptad repeat (HR2), to escape inhibition by an HR1 peptide, but preferentially selected the HR1 pathway to escape inhibition by a trimer-stabilized HR1 peptide. Here, we report that an X4 virus selected the same HR1 and HR2 resistance pathways as the R5 virus to escape inhibition by the HR1 peptide. However, in contrast to the R5 virus, the X4 virus selected a unique mutation in HR2 to escape inhibition by the trimer-stabilized peptide. Significantly, both of these X4 and R5 viruses acquired gp41 resistance mutations that improved the thermostability of the six-helix bundle, but they selected different gp120 adaptive mutations. These findings show that these X4 and R5 viruses use a similar resistance mechanism to escape from HR1 peptide inhibition but different gp120-gp41 interactions to regulate Env conformational changes.

Indexed as

Anti-Retroviral AgentsDrug Resistance, ViralGlycoproteinsHEK293 CellsHIV-1HIV Envelope Protein gp120HIV Envelope Protein gp41HIV Fusion InhibitorsHIV InfectionsHIV SeropositivityHumansMutationProtein ConformationReceptors, CCR5Receptors, CXCR4Anti-Retroviral AgentsCCR5 protein, humanCXCR4 protein, humanGlycoproteinsHIV Envelope Protein gp120HIV Envelope Protein gp41HIV Fusion InhibitorsReceptors, CCR5Receptors, CXCR4conformational changesfusionfusion inhibitorgp41HIV-1resistance

Identifiers

PMID30894471
PMCPMC6532104
OpenAlexW2923552469

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.